Open AccessPersonalized Approach of Severe Eosinophilic Asthma Patients Treated with Mepolizumab and Benralizumab
Author(s) -
Laura Bergantini,
Miriana d’Alessandro,
Paolo Cameli,
Francesco Paolo Bianchi,
Piersante Sestini,
Elena Bargagli,
Rosa Metella Refini
Publication year - 2020
Publication title -
international archives of allergy and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.696
H-Index - 100
eISSN - 1423-0097
pISSN - 1018-2438
DOI - 10.1159/000508936
Subject(s) - medicine , mepolizumab , benralizumab , asthma , cohort , immunology , eosinophil , vital capacity , gastroenterology , lung , diffusing capacity , lung function
New anti-IL-5 antibodies, mepolizumab and benralizumab, have recently been approved for severe asthma, sharing the same inclusion criteria.